

**Marketing Approval Granted for Melatobel Tablet 1 mg/2 mg for Pediatric,
A Melatonin Receptor Agonist that Improves the Sleep Onset**

Nobelpharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo/Managing Director & CEO: Jin Shiomura) announced that its “Melatobel Tablet 1 mg/2 mg for pediatric” has been approved on March 14 for sleep-onset difficulty associated with neurodevelopmental disorder in children.

This product proved to be bioequivalent to the original drug already available in granule form.

Some of the pediatric patients with neurodevelopmental disorders present with hypergeusia and/or hyperesthesia as nature of this disorder, which may lead to refusal of medication due to the property of granules. To provide the solution to such an issue, the tablet form of this product was developed.

We hope the launch of this product will be of some help to improve sleep onset in children with neurodevelopmental disorders.

Nobelpharma is determined to continue contribution to society by providing critical but neglected pharmaceuticals and medical devices.

[Contact for Inquiries]

Etsuro Hayashi, Head of Communications

Nobelpharma Co., Ltd.

1-17-24, Shinkawa, Chuo-ku, Tokyo 104-0033

Tel: 03-6670-3800